Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Novo Nordisk's head of US operations, James Millar, said the list price reductions are "the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the US." He went on to say that "private and public payers, as well as patients, want access and have been calling for lower list prices." It is estimated that around one in eight people in the US were taking incretin medicines for weight loss in 2025, according to KFF Health
2024, [5] A
What you need to know about GLP-1s Youve asked, and weve answered - your top questions about how Omada can help with your strategy for addressing GLP-1s
Im not pleased enough with it
- AstraGin 50mg gip ti u ha vic hp th cc cht dinh dng
